Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
3F., NO. 607, Ruiguang Rd., Neihu Dist., Taipei City, 11492, TW
Treatment for hemophilia A remains a significant unmet medical need.
By: Patrick Lavery
Access to twice-yearly lenacapavir for HIV prevention will be accelerated to all PAHO member states in these regions.
Phase 1 study will evaluate TLN-121 with Roche’s glofitamab and mosunetuzumab in patients with B-cell lymphomas.
By: Charlie Sternberg
Bixlenvo becomes the first, and smallest, once-daily single-tablet regimen available.
Henlius grants Sandoz exclusive registration and commercialization rights, outside China, for up to 10 products.
Dr. Reddy’s Laboratories developed, manufactured, and submitted the product for approval.
Halozyme’s proprietary Enhanze drug delivery tech may have potential to strengthen formulations currently in development.
SBT-77-7101 becomes the first Treg cell therapy program onboarded to the Cell Shuttle platform.
Agreement gives Teva exclusive commercialization rights to proposed ocrelizumab biosimilar in key global markets.
The monoclonal antibody is in Phase III development for treatment of von Willebrand disease, or VWD.
Roche will supply atezolizumab to be used in proposed clinical studies.
Aims to advance MabionCD20 for potential use in rare diseases, reactivating the company's CD20 program through a new orphan drug development strategy.
By: Kristin Brooks
The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies.
Production is transitioning from Gropello Cairoli, Italy, within the Farmabios business unit.
The companies will analyze ctDNA and real-world data to support leronlimab development in metastatic colorectal cancer.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
